PART IV — FORMULATION SCIENCE
Functional Matrix
Chapter 13
13.1 Introduction
The Functional Matrix defines the intended role of a SIRIAM formulation within the overall treatment architecture.
Rather than describing the pharmacological properties of individual ingredients, the Functional Matrix specifies the design objective that the formulation is intended to support.
Ingredient selection follows this functional objective and may evolve over time without changing the underlying formulation philosophy.
13.2 Functional Architecture
Within the SIRIAM Platform, every regional formulation is developed according to a standardized functional architecture.
The Functional Matrix consists of three successive stages:
Release
↓
Integration
↓
Maintenance
These stages form the basis of the DUO Architecture and guide the progression of topical application throughout the treatment process.
13.3 Release Phase
The Release phase represents the initial stage of the formulation strategy.
Its objective is to support the transition from an identified dysfunctional state toward improved neurodermal adaptability within the selected Application Field.
The Release formulation is therefore designed to provide the initial functional stimulus defined within the SIRIAM treatment architecture.
The duration of this phase is determined by Biological Readiness rather than by a fixed treatment period.
13.4 Integration Phase
Following the Release phase, the formulation transitions to the Integration phase.
The objective of Integration is to support consolidation of the functional changes initiated during Release.
Within the SIRIAM Platform, Integration is regarded as an active phase rather than a passive continuation of treatment.
The Integration formulation therefore possesses its own Functional Matrix and is not merely a lower-concentration version of the Release formulation.
13.5 Maintenance Phase
Following successful completion of the DUO sequence, the formulation enters the Maintenance phase.
Maintenance aims to support long-term continuity of the achieved functional state.
The frequency of application is determined by clinical reassessment and individual response.
Maintenance may include periodic application of the Integration formulation or other platform strategies depending on clinical evaluation.
13.6 Functional Independence
The Functional Matrix remains independent of the pharmaceutical composition.
A modification in ingredient concentration does not necessarily alter the functional identity of the formulation.
Conversely, a formulation may require substantial compositional changes while preserving its original functional objective.
This principle enables continuous pharmaceutical optimization without compromising platform consistency.
13.7 Relationship with the Structural Matrix
The Functional Matrix is built upon the Structural Matrix.
The Structural Matrix provides the pharmaceutical framework.
The Functional Matrix defines the intended functional direction.
Only after both matrices have been established are Regional Signature Components introduced.
13.8 Relationship with the Regional Signature Matrix
The Functional Matrix is identical in principle throughout the SIRIAM Platform.
Regional differentiation arises only after the Functional Matrix has been defined.
Consequently:
OAA
CTO
TLO
SX
Plexus formulations
all share the same functional architecture while differing in their Regional Signature Matrix.
This modular approach allows future platform expansion without redesigning the overall treatment philosophy.
13.9 Biological Readiness
Progression between Release and Integration is determined by Biological Readiness.
Biological Readiness combines:
Patient Assessment (Application Field Readiness Score – Patient)
Clinical Assessment (Application Field Readiness Score – Clinician)
The transition occurs only after both assessments indicate sufficient readiness.
The Functional Matrix therefore adapts to the biological response of the individual rather than following a predetermined schedule.
13.10 Functional Continuity
The Functional Matrix provides continuity across all regional formulations.
Regardless of anatomical location, every formulation follows the same functional progression:
Initial support (Release)
Functional consolidation (Integration)
Long-term support (Maintenance)
This continuity contributes to the coherence of the overall SIRIAM Platform.
13.11 Functional Flexibility
Although the Functional Matrix follows a standardized architecture, clinical application remains individualized.
Treatment duration, progression and maintenance intervals may vary according to:
Clinical Assessment
Biological Readiness
Patient response
Evolution of the targeted Application Field
The standardized architecture therefore supports individualized care within a reproducible framework.
13.12 Future Development
As the SIRIAM Platform evolves, the Functional Matrix may be refined through:
future research initiatives.
Such refinements shall preserve the core principles of the DUO Architecture while allowing controlled platform evolution.
Professional Review Notes (Anouck Van Aerschot)
Review 13.1 – Release vs. Integration
☐ Beoordelen of de huidige verschillen tussen Release- en Integration-formules farmaceutisch voldoende onderscheidend zijn.
☐ Adviseren of bepaalde structurele componenten beter identiek of juist verschillend blijven.
Review 13.2 – Stabiliteit tussen fasen
☐ Vergelijken of beide fasen een gelijke fysische stabiliteit behouden.
☐ Eventuele invloed van gewijzigde concentraties op viscositeit en homogeniteit documenteren.
Review 13.3 – Platformharmonisatie
☐ Nagaan of Release- en Integration-formules onderling verder kunnen worden gestandaardiseerd zonder verlies van hun functionele identiteit.
Review 13.4 – Productie
☐ Controleren of beide fasen volgens een identieke bereidingsprocedure kunnen worden vervaardigd.
☐ Afwijkingen in bereidingsvolgorde of temperatuurvensters documenteren indien noodzakelijk.
Review 13.5 – Master Formula
☐ Na farmaceutische validatie bevestigen dat iedere DUO-formulering een reproduceerbare Release- en Integration-versie bezit.
✦ Editor's R&D Note (werkversie)
Dit hoofdstuk beschrijft bewust de ontwerpfilosofie en niet de werking van individuele ingrediënten of klinische effectiviteit. Het maakt toekomstige optimalisatie mogelijk zonder de architectuur te wijzigen. Bij latere updates kunnen Release- en Integration-profielen evolueren op basis van farmaceutische ervaring, klinische observaties en onderzoeksgegevens, terwijl de onderliggende Functionele Matrix ongewijzigd blijft.
- pharmaceutical optimization;
- clinical observations;
- multidisciplinary review;